87 related articles for article (PubMed ID: 24275675)
1. Can antiretroviral therapy prevent HIV-associated cognitive disorders?
Winston A; Vera JH
Curr Opin HIV AIDS; 2014 Jan; 9(1):11-6. PubMed ID: 24275675
[TBL] [Abstract][Full Text] [Related]
2. European mitochondrial haplogroups are associated with CD4+ T cell recovery in HIV-infected patients on combination antiretroviral therapy.
Guzmán-Fulgencio M; Berenguer J; Micheloud D; Fernández-Rodríguez A; García-Álvarez M; Jiménez-Sousa MA; Bellón JM; Campos Y; Cosín J; Aldámiz-Echevarría T; Catalán P; López JC; Resino S
J Antimicrob Chemother; 2013 Oct; 68(10):2349-57. PubMed ID: 23749950
[TBL] [Abstract][Full Text] [Related]
3. Low rates of neurocognitive impairment are observed in neuro-asymptomatic HIV-infected subjects on effective antiretroviral therapy.
Garvey L; Surendrakumar V; Winston A
HIV Clin Trials; 2011; 12(6):333-8. PubMed ID: 22189152
[TBL] [Abstract][Full Text] [Related]
4. Risk of clinical progression among patients with immunological nonresponse despite virological suppression after combination antiretroviral treatment.
Lapadula G; Cozzi-Lepri A; Marchetti G; Antinori A; Chiodera A; Nicastri E; Parruti G; Galli M; Gori A; Monforte Ad;
AIDS; 2013 Mar; 27(5):769-79. PubMed ID: 23719349
[TBL] [Abstract][Full Text] [Related]
5. Mortality by baseline CD4 cell count among HIV patients initiating antiretroviral therapy: evidence from a large cohort in Uganda.
Mills EJ; Bakanda C; Birungi J; Mwesigwa R; Chan K; Ford N; Hogg RS; Cooper C
AIDS; 2011 Mar; 25(6):851-5. PubMed ID: 21330903
[TBL] [Abstract][Full Text] [Related]
6. Long-term response to combination antiretroviral therapy in HIV-infected children in the Netherlands registered from 1996 to 2012.
Cohen S; Smit C; van Rossum AM; Fraaij PL; Wolfs TF; Geelen SP; Schölvinck EH; Warris A; Scherpbier HJ; Pajkrt D;
AIDS; 2013 Oct; 27(16):2567-75. PubMed ID: 23842124
[TBL] [Abstract][Full Text] [Related]
7. Does antiretroviral therapy improve HIV-associated cognitive impairment? A quantitative review of the literature.
Al-Khindi T; Zakzanis KK; van Gorp WG
J Int Neuropsychol Soc; 2011 Nov; 17(6):956-69. PubMed ID: 21813033
[TBL] [Abstract][Full Text] [Related]
8. Risk factors for osteonecrosis in HIV-infected patients: impact of treatment with combination antiretroviral therapy.
Mary-Krause M; Billaud E; Poizot-Martin I; Simon A; Dhiver C; Dupont C; Salmon D; Roudiere L; Costagliola D;
AIDS; 2006 Aug; 20(12):1627-35. PubMed ID: 16868444
[TBL] [Abstract][Full Text] [Related]
9. Feasibility and effectiveness of early initiation of combination antiretroviral therapy in HIV-infected infants in a government clinic of Kwazulu-Natal, South Africa.
Purchase SE; Van der Linden DJ; McKerrow NH
J Trop Pediatr; 2012 Apr; 58(2):114-9. PubMed ID: 21705764
[TBL] [Abstract][Full Text] [Related]
10. Could antiretroviral neurotoxicity play a role in the pathogenesis of cognitive impairment in treated HIV disease?
Underwood J; Robertson KR; Winston A
AIDS; 2015 Jan; 29(3):253-61. PubMed ID: 25426811
[TBL] [Abstract][Full Text] [Related]
11. Interruption of combination antiretroviral therapy and risk of clinical disease progression to AIDS or death.
Holkmann Olsen C; Mocroft A; Kirk O; Vella S; Blaxhult A; Clumeck N; Fisher M; Katlama C; Phillips AN; Lundgren JD;
HIV Med; 2007 Mar; 8(2):96-104. PubMed ID: 17352766
[TBL] [Abstract][Full Text] [Related]
12. Rating evidence in treatment guidelines: a case example of when to initiate combination antiretroviral therapy (cART) in HIV-positive asymptomatic persons.
Sabin CA; Cooper DA; Collins S; Schechter M
AIDS; 2013 Jul; 27(12):1839-46. PubMed ID: 24179998
[TBL] [Abstract][Full Text] [Related]
13. Attenuated central nervous system infection in advanced HIV/AIDS with combination antiretroviral therapy.
McArthur JC; McDermott MP; McClernon D; St Hillaire C; Conant K; Marder K; Schifitto G; Selnes OA; Sacktor N; Stern Y; Albert SM; Kieburtz K; deMarcaida JA; Cohen B; Epstein LG
Arch Neurol; 2004 Nov; 61(11):1687-96. PubMed ID: 15534180
[TBL] [Abstract][Full Text] [Related]
14. Fungal infection as a risk factor for HIV disease progression among patients with a CD4 count above 200/microl in the era of cART.
Podlekareva D; Mocroft A; Kirk O; Reiss P; Aldins P; Katlama C; Kovari H; Stellbrink HJ; D'Arminio Monforte A; Lundgren JD;
Scand J Infect Dis; 2008; 40(11-12):908-13. PubMed ID: 18609197
[TBL] [Abstract][Full Text] [Related]
15. Antiretroviral therapy improves cognitive impairment in HIV+ individuals in sub-Saharan Africa.
Sacktor N; Nakasujja N; Skolasky R; Robertson K; Wong M; Musisi S; Ronald A; Katabira E
Neurology; 2006 Jul; 67(2):311-4. PubMed ID: 16864825
[TBL] [Abstract][Full Text] [Related]
16. Predictors of symptomatic HIV-associated neurocognitive disorders in universal health care.
McCombe JA; Vivithanaporn P; Gill MJ; Power C
HIV Med; 2013 Feb; 14(2):99-107. PubMed ID: 22994556
[TBL] [Abstract][Full Text] [Related]
17. When to start antiretroviral therapy?
Wilkin TJ; Gulick RM
Clin Infect Dis; 2008 Dec; 47(12):1580-6. PubMed ID: 18990069
[TBL] [Abstract][Full Text] [Related]
18. Changes over time in risk of initial virological failure of combination antiretroviral therapy: a multicohort analysis, 1996 to 2002.
Lampe FC; Gatell JM; Staszewski S; Johnson MA; Pradier C; Gill MJ; de Lazzari E; Dauer B; Youle M; Fontas E; Krentz HB; Phillips AN
Arch Intern Med; 2006 Mar; 166(5):521-8. PubMed ID: 16534038
[TBL] [Abstract][Full Text] [Related]
19. Rapid suppression of HIV-RNA is associated with improved control of immune activation in Mozambican adults initiating antiretroviral therapy with low CD4 counts.
Almeida JM; Letang E; Nhampossa T; Ayala E; David C; Menendez C; Gascon J; Alonso P; Naniche D
AIDS Res Hum Retroviruses; 2011 Jul; 27(7):705-11. PubMed ID: 21091388
[TBL] [Abstract][Full Text] [Related]
20. Relationship between CD4 cell count and serious long-term complications among HIV-positive individuals.
Achhra AC; Petoumenos K; Law MG
Curr Opin HIV AIDS; 2014 Jan; 9(1):63-71. PubMed ID: 24275674
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
